Physician profile

Matthew Paul Cyphers

Nephrology (Internal Medicine) · Grand Junction, CO

NPI 1437110954

$277.16

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

See the full distribution for Nephrology (Internal Medicine)

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$161.66
Education$13.60

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $56.52 2019-2024 Farxiga
Calliditas Therapeutics US INC. $50.23 2023-2024 Tarpeyo
Amgen INC. $44.39 2024 Tavneos
Otsuka America Pharmaceutical, INC. $41.56 2019-2023 Jynarque
Mallinckrodt Enterprises LLC $23.07 2019
Travere Therapeutics, INC. $20.89 2024
Genentech USA, INC. $15.90 2019
Medtronic, INC. $12.67 2021
Alexion Pharmaceuticals, INC. $11.93 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Matthew Paul Cyphers

$277.16

in general payments reported 2019-2025

Years
2019-2024
Top company
Astrazeneca Pharmaceuticals LP

https://glasscript.com/doctor/973542/matthew-paul-cyphers

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Download CSV

The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.